Skip Navigation


NDT Advance Access originally published online on May 21, 2008
Nephrology Dialysis Transplantation 2008 23(8):2450-2453; doi:10.1093/ndt/gfn267
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/8/2450    most recent
gfn267v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Swinkels, D. W.
Right arrow Articles by Wetzels, J. F. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swinkels, D. W.
Right arrow Articles by Wetzels, J. F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org


Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?

Dorine W. Swinkels1 and Jack F. M. Wetzels2

1 Department of Clinical Chemistry 2 Department of Nephrology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

Correspondence and offprint requests to: Dorine W. Swinkels, Department of Clinical Chemistry (441), Radboud University Nijmegen Medical Centre, PO Box 9101, 6500 HB Nijmegen,The Netherlands. Tel: +31-24-3618957; Fax: +31-24-3541743; E-mail: D.Swinkels@akc.umcn.nl

Keywords: chronic kidney disease; erythropoietin; hepcidin; inflammation; iron

The first 150 words of the full text of this article appear below.



   Introduction
 
The introduction of erythropoiesis-stimulating agents (ESA), such as recombinant human erythropoietin (EPO) has allowed effective treatment of anaemia in patients with chronic kidney disease (CKD). However, the optimal target level of haemoglobin is debated and many patients are resistant to ESA.

Hepcidin is a recently discovered low-molecular-weight protein that plays an important role in iron metabolism. Hepcidin may be relevant in CKD and explain the often-observed disbalance in iron metabolism and the resistance to ESA. As such hepcidin could become an important tool to predict ESA responsiveness and to guide treatment with ESA and intravenous iron. In addition, hepcidin has the potential to become a target of treatment. In this review we summarize the pathophysiology of hepcidin and discuss its potential relevance for patients with CKD.



   Hepcidin: physiology
 
Human hepcidin is produced by hepatocytes as an 84-amino-acid (aa) pre-prohepcidin [1]. Subsequent posttranslational processing results in the biologically active 25 aa . . . [Full Text of this Article]



   Measurement of hepcidin
 


   Hepcidin in patients with chronic kidney diseases
 


   Hepcidin and anaemia of chronic kidney diseases
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?